Loading
Liver Disease Diagnosis and Treatment / Gastrointestinal Motility and Disorders · Journal article
Frontiers in Pharmacology · August 13, 2026
A consensus or society position rather than new primary data.
This is a narrative review that synthesizes current understanding of the gut-liver axis in MASLD, focusing on mechanistic dysregulation involving microbial composition, intestinal barrier function, metabolite disturbances, and immune dysregulation. The review identifies potential therapeutic approaches including fecal microbiota transplantation and natural products, but does not report original clinical trial data or effect estimates to support specific interventions.
Narrative review. Adults worldwide; focus on populations with obesity, type 2 diabetes, and related metabolic abnormalities..
MASLD affects more than one-third of adults worldwide and is expected to increase with rising obesity and type 2 diabetes. Gut microbiota dysregulation contributes to MASLD through alterations in microbial composition, intestinal barrier injury, microbiota-derived metabolite disturbances, and immune dysregulation. Therapeutic strategies targeting gut microbiota, including fecal microbiota transplantation and natural products, may provide new opportunities for MASLD prevention and treatment.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review provides a mechanistic framework for understanding MASLD pathogenesis via gut-liver axis dysregulation and identifies potential targets for therapeutic intervention. Clinicians should recognize that microbiota-directed therapies remain in the exploratory stage and require confirmatory clinical evidence before routine implementation.
A narrative review synthesizing mechanistic understanding of gut-liver axis dysregulation in MASLD, offering a framework for understanding disease pathways and therapeutic targets rather than reporting original evidence.
As stated by the source record.
Quoted from the source exactly as published.
This review provides a mechanistic framework for understanding MASLD pathogenesis via gut-liver axis dysregulation and identifies potential targets for therapeutic intervention. Clinicians should recognize that microbiota-directed therapies remain in the exploratory stage and require confirmatory clinical evidence before routine implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most common chronic liver diseases worldwide, affecting more than one-third of adults and imposing a substantial hepatic and systemic metabolic burden. With the continuing rise in obesity, type 2 diabetes mellitus, and related metabolic abnormalities, the prevalence of MASLD is expected to keep increasing. This review summarizes MASLD from the overarching perspective of gut-liver axis dysregulation, focusing on alterations in gut microbial composition and function, intestinal barrier injury, disturbances in microbiota-derived metabolites, and gut microbiota-associated epigenetic and immune dysregulation during disease initiation and progression. It further integrates the overall significance of these changes in the evolution of MASLD. Finally, potential therapeutic strategies represented by fecal microbiota transplantation and natural products are briefly discussed, suggesting that targeting the gut microbiota and its related networks may provide new opportunities for MASLD prevention and treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.